{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:51:19Z","timestamp":1792363879920,"version":"4.4.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Amyloid-beta (A\u03b2) plaque formation in Alzheimer\u2019s disease (AD) pathology is morphologically diverse. Understanding the association of polymorphic A\u03b2 pathology with AD pathogenesis and progression is critical in light of emerging A\u03b2-targeting therapies. In this work, functional amyloid microscopy enhanced by deep learning was integrated with mass spectrometry imaging to delineate polymorphic plaques and to\u00a0identify their associated A\u03b2 make-up. In both sporadic AD (<jats:italic>n<\/jats:italic>\u2009=\u200912) and familial AD (<jats:italic>n<\/jats:italic>\u2009=\u20096), dense-core plaques showed higher levels of A\u03b21-40 and N-terminal pyroglutamated A\u03b2x-42 compared to diffuse plaques and plaques in non-demented, amyloid positive individuals (<jats:italic>n<\/jats:italic>\u2009=\u20095). Notably, a distinct dense-core plaque subtype, coarse-grained plaque, was observed in AD but not in non-demented, amyloid positive patients. Coarse-grained plaques were more abundant in early onset AD, showed increased neuritic dystrophy and higher levels of A\u03b21-40 and A\u03b23pE-40, an A\u03b2-pattern similar to cerebral amyloid angiopathy. The correlative chemical imaging paradigm presented here allowed to link structural and biochemical characteristics of A\u03b2 plaque polymorphism across various AD etiologies.<\/jats:p>","DOI":"10.1038\/s41467-025-59085-7","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T17:02:00Z","timestamp":1745514120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Chemical imaging delineates A\u03b2 plaque polymorphism across the Alzheimer\u2019s disease spectrum"],"prefix":"10.1038","volume":"16","author":[{"given":"Srinivas","family":"Koutarapu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9542-802X","authenticated-orcid":false,"given":"Junyue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7149-017X","authenticated-orcid":false,"given":"Maciej","family":"Dulewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Srikrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-9309","authenticated-orcid":false,"given":"Alicja","family":"Szadziewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-4020","authenticated-orcid":false,"given":"Jack","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-3604","authenticated-orcid":false,"given":"Wojciech","family":"Michno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-0348","authenticated-orcid":false,"given":"Tammaryn","family":"Lashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-5580","authenticated-orcid":false,"given":"Jeffrey N.","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1781","authenticated-orcid":false,"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-198X","authenticated-orcid":false,"given":"J\u00f6rg","family":"Hanrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"59085_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jalz.2018.06.3063","volume":"15","author":"KA Matthews","year":"2019","unstructured":"Matthews, K. A. et al. Racial and ethnic estimates of Alzheimer\u2019s disease and related dementias in the United States (2015-2060) in adults aged \u226565 years. Alzheimers Dement 15, 17\u201324 (2019).","journal-title":"Alzheimers Dement"},{"key":"59085_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica 82, 239\u2013259 (1991).","journal-title":"Acta neuropathologica"},{"key":"59085_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. Medicine - The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"59085_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe, D. J. Alzheimer\u2019s disease is a synaptic failure. Science 298, 789\u2013791 (2002).","journal-title":"Science"},{"key":"59085_CR5","doi-asserted-by":"publisher","unstructured":"Hayato, S. et al. Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer\u2019s disease. CPT Pharmacometrics Syst. Pharmacol. https:\/\/doi.org\/10.1002\/psp4.12862 (2022).","DOI":"10.1002\/psp4.12862"},{"key":"59085_CR6","doi-asserted-by":"publisher","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12748 (2022).","DOI":"10.1002\/alz.12748"},{"key":"59085_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trci.2016.01.001","volume":"2","author":"A Satlin","year":"2016","unstructured":"Satlin, A. et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer\u2019s disease. Alzheimers Dement (N.Y.) 2, 1\u201312 (2016).","journal-title":"Alzheimers Dement (N.Y.)"},{"key":"59085_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 13, 80 (2021).","journal-title":"Alzheimers Res Ther."},{"key":"59085_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in Early Alzheimer\u2019s Disease. N. Engl. J. Med 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med"},{"key":"59085_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"59085_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in Early Alzheimer\u2019s Disease. N. Engl. J. Med 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med"},{"key":"59085_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/0166-2236(92)90033-5","volume":"15","author":"J Hardy","year":"1992","unstructured":"Hardy, J. An anatomical cascade hypothesis for Alzheimer\u2019s disease. Trends Neurosci. 15, 200\u2013201 (1992).","journal-title":"Trends Neurosci."},{"key":"59085_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00005072-199704000-00001","volume":"56","author":"DW Dickson","year":"1997","unstructured":"Dickson, D. W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56, 321\u2013339 (1997).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"59085_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jnen\/nlac030","volume":"81","author":"TG Beach","year":"2022","unstructured":"Beach, T. G. A History of Senile Plaques: From Alzheimer to Amyloid Imaging. J. Neuropathol. Exp. Neurol. 81, 387\u2013413 (2022).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"59085_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF00688170","volume":"78","author":"HM Wisniewski","year":"1989","unstructured":"Wisniewski, H. M., Bancher, C., Barcikowska, M., Wen, G. Y. & Currie, J. Spectrum of morphological appearance of amyloid deposits in Alzheimer\u2019s disease. Acta neuropathologica 78, 337\u2013347 (1989).","journal-title":"Acta neuropathologica"},{"key":"59085_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/jnen\/62.9.885","volume":"62","author":"T Revesz","year":"2003","unstructured":"Revesz, T. et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J. Neuropathol. Exp. Neurol. 62, 885\u2013898 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"59085_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1176\/ajp.67.3.503","volume":"67","author":"A Barrett","year":"1911","unstructured":"Barrett, A. Degenerations of intracellular neurofibrils with miliary gliosis in psychoses of the senile period. Am. J. Psychiatry 67, 503\u2013516 (1911).","journal-title":"Am. J. Psychiatry"},{"key":"59085_CR18","first-page":"269","volume":"44","author":"RD Terry","year":"1964","unstructured":"Terry, R. D., Gonatas, N. K. & Weiss, M. ULTRASTRUCTURAL STUDIES IN ALZHEIMER\u2019S PRESENILE DEMENTIA. Am. J. Pathol. 44, 269\u2013297 (1964).","journal-title":"Am. J. Pathol."},{"key":"59085_CR19","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1007\/s12035-023-03736-7","volume":"61","author":"W Tsering","year":"2024","unstructured":"Tsering, W. & Prokop, S. Neuritic Plaques \u2014 Gateways to Understanding Alzheimer\u2019s Disease. Mol. Neurobiol. 61, 2808\u20132821 (2024).","journal-title":"Mol. Neurobiol."},{"key":"59085_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00310918","volume":"82","author":"H Yamaguchi","year":"1991","unstructured":"Yamaguchi, H., Nakazato, Y., Shoji, M., Takatama, M. & Hirai, S. Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques. Acta Neuropathologica 82, 13\u201320 (1991).","journal-title":"Acta Neuropathologica"},{"key":"59085_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/00005072-199902000-00010","volume":"58","author":"DR Thal","year":"1999","unstructured":"Thal, D. R. et al. Fleecy Amyloid Deposits in the Internal Layers of the Human Entorhinal Cortex are Comprised of N-terminal Truncated Fragments of A\u03b2. J. Neuropathol. Exp. Neurol. 58, 210\u2013216 (1999).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"59085_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm0498-452","volume":"4","author":"R Crook","year":"1998","unstructured":"Crook, R. et al. A variant of Alzheimer\u2019s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4, 452\u2013455 (1998).","journal-title":"Nat. Med."},{"key":"59085_CR23","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3233\/JAD-160365","volume":"53","author":"M Malek-Ahmadi","year":"2016","unstructured":"Malek-Ahmadi, M., Perez, S. E., Chen, K. & Mufson, E. J. Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly. J. Alzheimer\u2019s. Dis. 53, 1641\u20131652 (2016).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"59085_CR24","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1097\/NEN.0000000000000016","volume":"72","author":"A Serrano-Pozo","year":"2013","unstructured":"Serrano-Pozo, A. et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J. Neuropathol. Exp. Neurol. 72, 1182\u20131192 (2013).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"59085_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","volume":"3","author":"CA Lemere","year":"1996","unstructured":"Lemere, C. A. et al. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16\u201332 (1996).","journal-title":"Neurobiol. Dis."},{"key":"59085_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/BF00305876","volume":"81","author":"P Dela\u00e8re","year":"1991","unstructured":"Dela\u00e8re, P., Duyckaerts, C., He, Y., Piette, F. & Hauw, J. J. Subtypes and differential laminar distributions of beta A4 deposits in Alzheimer\u2019s disease: relationship with the intellectual status of 26 cases. Acta neuropathologica 81, 328\u2013335 (1991).","journal-title":"Acta neuropathologica"},{"key":"59085_CR27","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1212\/WNL.38.11.1682","volume":"38","author":"H Crystal","year":"1988","unstructured":"Crystal, H. et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer\u2019s disease. Neurology 38, 1682\u20131687 (1988).","journal-title":"Neurology"},{"key":"59085_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0197-4580(92)90027-U","volume":"13","author":"DW Dickson","year":"1992","unstructured":"Dickson, D. W. et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13, 179\u2013189 (1992).","journal-title":"Neurobiol. Aging"},{"key":"59085_CR29","first-page":"1823","volume":"149","author":"T Iwatsubo","year":"1996","unstructured":"Iwatsubo, T., Saido, T. C., Mann, D. M., Lee, V. M. & Trojanowski, J. Q. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am. J. Pathol. 149, 1823\u20131830 (1996).","journal-title":"Am. J. Pathol."},{"key":"59085_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0896-6273(95)90301-1","volume":"14","author":"TC Saido","year":"1995","unstructured":"Saido, T. C. et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14, 457\u2013466 (1995).","journal-title":"Neuron"},{"key":"59085_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awt362","volume":"137","author":"A Rijal Upadhaya","year":"2014","unstructured":"Rijal Upadhaya, A. et al. Biochemical stages of amyloid-\u03b2 peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer\u2019s disease. Brain 137, 887\u2013903 (2014).","journal-title":"Brain"},{"key":"59085_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jneuroim.2010.08.020","volume":"229","author":"R Perez-Garmendia","year":"2010","unstructured":"Perez-Garmendia, R. et al. Anti-11[E]-pyroglutamate-modified amyloid \u03b2 antibodies cross-react with other pathological A\u03b2 species: relevance for immunotherapy. J. Neuroimmunol. 229, 248\u2013255 (2010).","journal-title":"J. Neuroimmunol."},{"key":"59085_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/abbi.1993.1112","volume":"301","author":"DL Miller","year":"1993","unstructured":"Miller, D. L. et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer\u2019s disease. Arch. Biochem Biophys. 301, 41\u201352 (1993).","journal-title":"Arch. Biochem Biophys."},{"key":"59085_CR34","doi-asserted-by":"publisher","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","volume":"267","author":"H Mori","year":"1992","unstructured":"Mori, H., Takio, K., Ogawara, M. & Selkoe, D. J. Mass spectrometry of purified amyloid beta protein in Alzheimer\u2019s disease. J. Biol. Chem. 267, 17082\u201317086 (1992).","journal-title":"J. Biol. Chem."},{"key":"59085_CR35","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1073\/pnas.91.18.8378","volume":"91","author":"J N\u00e4slund","year":"1994","unstructured":"N\u00e4slund, J. et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl Acad. Sci. USA 91, 8378\u20138382 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59085_CR36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jnc.14559","volume":"151","author":"W Michno","year":"2019","unstructured":"Michno, W., Wehrli, P. M., Blennow, K., Zetterberg, H. & Hanrieder, J. Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. J. Neurochem 151, 488\u2013506 (2019).","journal-title":"J. Neurochem"},{"key":"59085_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/jnc.13645","volume":"138","author":"L Carlred","year":"2016","unstructured":"Carlred, L. et al. Probing amyloid-beta pathology in transgenic Alzheimer\u2019s disease (tgArcSwe) mice using MALDI imaging mass spectrometry. J. Neurochem 138, 469\u2013478 (2016).","journal-title":"J. Neurochem"},{"key":"59085_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abg4855","volume":"7","author":"W Michno","year":"2021","unstructured":"Michno, W. et al. Following spatial A\u03b2 aggregation dynamics in evolving Alzheimer\u2019s disease pathology by imaging stable isotope labeling kinetics. Sci. Adv. 7, eabg4855 (2021).","journal-title":"Sci. Adv."},{"key":"59085_CR39","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/jnc.14888","volume":"152","author":"W Michno","year":"2020","unstructured":"Michno, W. et al. Chemical imaging of evolving amyloid plaque pathology and associated A\u03b2 peptide aggregation in a transgenic mouse model of Alzheimer\u2019s disease. J. Neurochem 152, 602\u2013616 (2020).","journal-title":"J. Neurochem"},{"key":"59085_CR40","doi-asserted-by":"publisher","unstructured":"Kaya, I. et al. Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer\u2019s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. ACS Chem. Neurosci. https:\/\/doi.org\/10.1021\/acschemneuro.6b00391 (2017).","DOI":"10.1021\/acschemneuro.6b00391"},{"key":"59085_CR41","doi-asserted-by":"publisher","unstructured":"Michno, W. et al. Pyroglutamation of amyloid-betax-42 (Abetax-42) followed by Abeta1-40 deposition underlies plaque polymorphism in progressing Alzheimer\u2019s disease pathology. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.RA118.006604 (2019).","DOI":"10.1074\/jbc.RA118.006604"},{"key":"59085_CR42","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1021\/cb4000376","volume":"8","author":"S Nystrom","year":"2013","unstructured":"Nystrom, S. et al. Evidence for age-dependent in vivo conformational rearrangement within Abeta amyloid deposits. ACS Chem. Biol. 8, 1128\u20131133 (2013).","journal-title":"ACS Chem. Biol."},{"key":"59085_CR43","doi-asserted-by":"publisher","first-page":"13018","DOI":"10.1073\/pnas.1713215114","volume":"114","author":"J Rasmussen","year":"2017","unstructured":"Rasmussen, J. et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 114, 13018\u201313023 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59085_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.108032","volume":"301","author":"T Klingstedt","year":"2024","unstructured":"Klingstedt, T. et al. Dual-ligand fluorescence microscopy enables chronological and spatial histological assignment of distinct amyloid-\u03b2 deposits. J. Biol. Chem. 301, 108032 (2024).","journal-title":"J. Biol. Chem."},{"key":"59085_CR45","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1021\/acschemneuro.4c00104","volume":"15","author":"F Parvin","year":"2024","unstructured":"Parvin, F. et al. Divergent Age-Dependent Conformational Rearrangement within A\u03b2 Amyloid Deposits in APP23, APPPS1, and App(NL-F) Mice. ACS Chem. Neurosci. 15, 2058\u20132069 (2024).","journal-title":"ACS Chem. Neurosci."},{"key":"59085_CR46","doi-asserted-by":"publisher","first-page":"e0304709","DOI":"10.1371\/journal.pone.0304709","volume":"19","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. Multimodal MALDI imaging mass spectrometry for improved diagnosis of melanoma. PLoS One 19, e0304709 (2024).","journal-title":"PLoS One"},{"key":"59085_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mas.21602","volume":"39","author":"N Verbeeck","year":"2020","unstructured":"Verbeeck, N., Caprioli, R. M. & Van de Plas, R. Unsupervised machine learning for exploratory data analysis in imaging mass spectrometry. Mass Spectrom. Rev. 39, 245\u2013291 (2020).","journal-title":"Mass Spectrom. Rev."},{"key":"59085_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40066-7","volume":"14","author":"Y Amitay","year":"2023","unstructured":"Amitay, Y. et al. CellSighter: a neural network to classify cells in highly multiplexed images. Nat. Commun. 14, 4302 (2023).","journal-title":"Nat. Commun."},{"key":"59085_CR49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41591-021-01343-4","volume":"27","author":"J van der Laak","year":"2021","unstructured":"van der Laak, J., Litjens, G. & Ciompi, F. Deep learning in histopathology: the path to the clinic. Nat. Med 27, 775\u2013784 (2021).","journal-title":"Nat. Med"},{"key":"59085_CR50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00401-020-02198-8","volume":"140","author":"BDC Boon","year":"2020","unstructured":"Boon, B. D. C. et al. The coarse-grained plaque: a divergent A\u03b2 plaque-type in early-onset Alzheimer\u2019s disease. Acta Neuropathologica 140, 811\u2013830 (2020).","journal-title":"Acta Neuropathologica"},{"key":"59085_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13009","volume":"32","author":"N Willumsen","year":"2022","unstructured":"Willumsen, N. et al. Variability in the type and layer distribution of cortical Abeta pathology in familial Alzheimer\u2019s disease. Brain Pathol. 32, e13009 (2022).","journal-title":"Brain Pathol."},{"key":"59085_CR52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/archneur.55.9.1185","volume":"55","author":"V Haroutunian","year":"1998","unstructured":"Haroutunian, V. et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch. Neurol. 55, 1185\u20131191 (1998).","journal-title":"Arch. Neurol."},{"key":"59085_CR53","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","volume":"360","author":"GM Savva","year":"2009","unstructured":"Savva, G. M. et al. Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302\u20132309 (2009).","journal-title":"N. Engl. J. Med."},{"key":"59085_CR54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/alzrt254","volume":"6","author":"ME Murray","year":"2014","unstructured":"Murray, M. E. & Dickson, D. W. Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer\u2019s disease? Alzheimers Res Ther. 6, 24 (2014).","journal-title":"Alzheimers Res Ther."},{"key":"59085_CR55","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan, N. S. et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol. 15, 1326\u20131335 (2016).","journal-title":"Lancet Neurol."},{"key":"59085_CR56","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0197-4580(97)00065-1","volume":"18","author":"DW Dickson","year":"1997","unstructured":"Dickson, D. W. Neuropathological diagnosis of Alzheimer\u2019s disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 18, S21\u201326 (1997).","journal-title":"Neurobiol. Aging"},{"key":"59085_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo, T. et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45\u201353 (1994).","journal-title":"Neuron"},{"key":"59085_CR58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/00005072-199801000-00009","volume":"57","author":"TL Tekirian","year":"1998","unstructured":"Tekirian, T. L. et al. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J. Neuropathol. Exp. Neurol. 57, 76\u201394 (1998).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"59085_CR59","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/0304-3940(86)90152-7","volume":"68","author":"D Allsop","year":"1986","unstructured":"Allsop, D. et al. Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer\u2019s disease. Neurosci. Lett. 68, 252\u2013256 (1986).","journal-title":"Neurosci. Lett."},{"key":"59085_CR60","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal, D. R., Walter, J., Saido, T. C. & F\u00e4ndrich, M. Neuropathology and biochemistry of A\u03b2 and its aggregates in Alzheimer\u2019s disease. Acta neuropathologica 129, 167\u2013182 (2015).","journal-title":"Acta neuropathologica"},{"key":"59085_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00401-006-0077-5","volume":"112","author":"K Liu","year":"2006","unstructured":"Liu, K. et al. Characterization of Abeta11-40\/42 peptide deposition in Alzheimer\u2019s disease and young Down\u2019s syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer\u2019s disease. Acta neuropathologica 112, 163\u2013174 (2006).","journal-title":"Acta neuropathologica"},{"key":"59085_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/alzrt121","volume":"4","author":"BD Moore","year":"2012","unstructured":"Moore, B. D. et al. Overlapping profiles of A\u03b2 peptides in the Alzheimer\u2019s disease and pathological aging brains. Alzheimers Res Ther. 4, 18 (2012).","journal-title":"Alzheimers Res Ther."},{"key":"59085_CR63","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1093\/brain\/awx284","volume":"140","author":"M Shinohara","year":"2017","unstructured":"Shinohara, M. et al. Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-\u03b242 in Alzheimer\u2019s disease. Brain 140, 3301\u20133316 (2017).","journal-title":"Brain"},{"key":"59085_CR64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00401-010-0690-1","volume":"120","author":"E Portelius","year":"2010","unstructured":"Portelius, E. et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer\u2019s disease. Acta neuropathologica 120, 185\u2013193 (2010).","journal-title":"Acta neuropathologica"},{"key":"59085_CR65","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.neuroscience.2006.08.027","volume":"143","author":"A G\u00fcntert","year":"2006","unstructured":"G\u00fcntert, A., D\u00f6beli, H. & Bohrmann, B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461\u2013475 (2006).","journal-title":"Neuroscience"},{"key":"59085_CR66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0304-3940(96)12970-0","volume":"215","author":"TC Saido","year":"1996","unstructured":"Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T. & Kawashima, S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 215, 173\u2013176 (1996).","journal-title":"Neurosci. Lett."},{"key":"59085_CR67","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/BF00689591","volume":"76","author":"H Yamaguchi","year":"1988","unstructured":"Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M. & Ihara, Y. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta neuropathologica 76, 541\u2013549 (1988).","journal-title":"Acta neuropathologica"},{"key":"59085_CR68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF00687420","volume":"77","author":"H Yamaguchi","year":"1988","unstructured":"Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M. & Harigaya, Y. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta neuropathologica 77, 113\u2013119 (1988).","journal-title":"Acta neuropathologica"},{"key":"59085_CR69","first-page":"593","volume":"135","author":"H Yamaguchi","year":"1989","unstructured":"Yamaguchi, H., Nakazato, Y., Hirai, S., Shoji, M. & Harigaya, Y. Electron micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer brain. Am. J. Pathol. 135, 593\u2013597 (1989).","journal-title":"Am. J. Pathol."},{"key":"59085_CR70","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/0304-3940(88)90706-9","volume":"91","author":"C Duyckaerts","year":"1988","unstructured":"Duyckaerts, C., Dela\u00e8re, P., Poulain, V., Brion, J. P. & Hauw, J. J. Does amyloid precede paired helical filaments in the senile plaque? A study of 15 cases with graded intellectual status in aging and Alzheimer disease. Neurosci. Lett. 91, 354\u2013359 (1988).","journal-title":"Neurosci. Lett."},{"key":"59085_CR71","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1074\/jbc.RA118.006604","volume":"294","author":"W Michno","year":"2019","unstructured":"Michno, W. et al. Pyroglutamation of amyloid-\u03b2x-42 (A\u03b2x-42) followed by A\u03b21-40 deposition underlies plaque polymorphism in progressing Alzheimer\u2019s disease pathology. J. Biol. Chem. 294, 6719\u20136732 (2019).","journal-title":"J. Biol. Chem."},{"key":"59085_CR72","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1006\/bbrc.2000.3490","volume":"276","author":"Y Harigaya","year":"2000","unstructured":"Harigaya, Y. et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer\u2019s disease brain. Biochem Biophys. Res Commun. 276, 422\u2013427 (2000).","journal-title":"Biochem Biophys. Res Commun."},{"key":"59085_CR73","doi-asserted-by":"publisher","first-page":"10871","DOI":"10.1021\/bi990563r","volume":"38","author":"W He","year":"1999","unstructured":"He, W. & Barrow, C. J. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry 38, 10871\u201310877 (1999).","journal-title":"Biochemistry"},{"key":"59085_CR74","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1006\/bbrc.1997.7083","volume":"237","author":"YM Kuo","year":"1997","unstructured":"Kuo, Y. M., Emmerling, M. R., Woods, A. S., Cotter, R. J. & Roher, A. E. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys. Res Commun. 237, 188\u2013191 (1997).","journal-title":"Biochem Biophys. Res Commun."},{"key":"59085_CR75","doi-asserted-by":"publisher","first-page":"16483","DOI":"10.1039\/D2CP05961D","volume":"25","author":"S Nath","year":"2023","unstructured":"Nath, S., Buell, A. K. & Barz, B. Pyroglutamate-modified amyloid \u03b2(3-42) monomer has more \u03b2-sheet content than the amyloid \u03b2(1-42) monomer. Phys. Chem. Chem. Phys. 25, 16483\u201316491 (2023).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"59085_CR76","doi-asserted-by":"publisher","first-page":"e0143647","DOI":"10.1371\/journal.pone.0143647","volume":"10","author":"C Dammers","year":"2015","unstructured":"Dammers, C. et al. Structural Analysis and Aggregation Propensity of Pyroglutamate A\u03b2(3-40) in Aqueous Trifluoroethanol. PLoS One 10, e0143647 (2015).","journal-title":"PLoS One"},{"key":"59085_CR77","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/S0197-4580(98)00033-5","volume":"19","author":"TC Saido","year":"1998","unstructured":"Saido, T. C. Alzheimer\u2019s disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol. Aging 19, S69\u201375 (1998).","journal-title":"Neurobiol. Aging"},{"key":"59085_CR78","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/oxfordjournals.jbchem.a022839","volume":"128","author":"Y Takaki","year":"2000","unstructured":"Takaki, Y. et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J. Biochem 128, 897\u2013902 (2000).","journal-title":"J. Biochem"},{"key":"59085_CR79","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1046\/j.1471-4159.2002.01107.x","volume":"82","author":"C Russo","year":"2002","unstructured":"Russo, C. et al. Pyroglutamate-modified amyloid beta-peptides-AbetaN3(pE)-strongly affect cultured neuron and astrocyte survival. J. Neurochem 82, 1480\u20131489 (2002).","journal-title":"J. Neurochem"},{"key":"59085_CR80","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","volume":"27","author":"TA Bayer","year":"2022","unstructured":"Bayer, T. A. Pyroglutamate A\u03b2 cascade as drug target in Alzheimer\u2019s disease. Mol. Psychiatry 27, 1880\u20131885 (2022).","journal-title":"Mol. Psychiatry"},{"key":"59085_CR81","doi-asserted-by":"publisher","first-page":"30322","DOI":"10.1074\/jbc.274.42.30322","volume":"274","author":"FJ Ekinci","year":"1999","unstructured":"Ekinci, F. J., Malik, K. U. & Shea, T. B. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. J. Biol. Chem. 274, 30322\u201330327 (1999).","journal-title":"J. Biol. Chem."},{"key":"59085_CR82","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/74833","volume":"3","author":"A Lorenzo","year":"2000","unstructured":"Lorenzo, A. et al. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer\u2019s disease. Nat. Neurosci. 3, 460\u2013464 (2000).","journal-title":"Nat. Neurosci."},{"key":"59085_CR83","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1523\/JNEUROSCI.12-02-00376.1992","volume":"12","author":"MP Mattson","year":"1992","unstructured":"Mattson, M. P. et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376\u2013389 (1992).","journal-title":"J. Neurosci."},{"key":"59085_CR84","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/1071576021000049890","volume":"36","author":"DA Butterfield","year":"2002","unstructured":"Butterfield, D. A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer\u2019s disease brain. A review. Free Radic. Res 36, 1307\u20131313 (2002).","journal-title":"Free Radic. Res"},{"key":"59085_CR85","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41380-019-0396-2","volume":"24","author":"MG Sharoar","year":"2019","unstructured":"Sharoar, M. G., Hu, X., Ma, X. M., Zhu, X. & Yan, R. Sequential formation of different layers of dystrophic neurites in Alzheimer\u2019s brains. Mol. Psychiatry 24, 1369\u20131382 (2019).","journal-title":"Mol. Psychiatry"},{"key":"59085_CR86","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/jnr.490390607","volume":"39","author":"L Otvos Jr.","year":"1994","unstructured":"Otvos, L. Jr. et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res 39, 669\u2013673 (1994).","journal-title":"J. Neurosci. Res"},{"key":"59085_CR87","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0006-8993(96)00811-6","volume":"739","author":"JH Su","year":"1996","unstructured":"Su, J. H., Cummings, B. J. & Cotman, C. W. Plaque biogenesis in brain aging and Alzheimer\u2019s disease: I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res. 739, 79\u201387 (1996).","journal-title":"Brain Res."},{"key":"59085_CR88","doi-asserted-by":"publisher","first-page":"II6","DOI":"10.1007\/BF03161076","volume":"246","author":"DW Dickson","year":"1999","unstructured":"Dickson, D. W. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J. Neurol. 246, II6\u2013II15 (1999).","journal-title":"J. Neurol."},{"key":"59085_CR89","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1046\/j.1471-4159.1999.0731584.x","volume":"73","author":"TL Tekirian","year":"1999","unstructured":"Tekirian, T. L., Yang, A. Y., Glabe, C. & Geddes, J. W. Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42. J. Neurochem 73, 1584\u20131589 (1999).","journal-title":"J. Neurochem"},{"key":"59085_CR90","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"R Vassar","year":"2009","unstructured":"Vassar, R., Kovacs, D. M., Yan, R. & Wong, P. C. The beta-secretase enzyme BACE in health and Alzheimer\u2019s disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 29, 12787\u201312794 (2009).","journal-title":"J. Neurosci."},{"key":"59085_CR91","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00401-013-1129-2","volume":"126","author":"Y Bouter","year":"2013","unstructured":"Bouter, Y. et al. N-truncated amyloid \u03b2 (A\u03b2) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta neuropathologica 126, 189\u2013205 (2013).","journal-title":"Acta neuropathologica"},{"key":"59085_CR92","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00401-014-1287-x","volume":"127","author":"TA Bayer","year":"2014","unstructured":"Bayer, T. A. & Wirths, O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer\u2019s disease. Acta neuropathologica 127, 787\u2013801 (2014).","journal-title":"Acta neuropathologica"},{"key":"59085_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40035-022-00303-3","volume":"11","author":"A Rostagno","year":"2022","unstructured":"Rostagno, A., Cabrera, E., Lashley, T. & Ghiso, J. N-terminally truncated A\u03b24-x proteoforms and their relevance for Alzheimer\u2019s pathophysiology. Transl. Neurodegener. 11, 30 (2022).","journal-title":"Transl. Neurodegener."},{"key":"59085_CR94","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1750-3639.2008.00244.x","volume":"20","author":"PT Nelson","year":"2010","unstructured":"Nelson, P. T. et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol. 20, 66\u201379 (2010).","journal-title":"Brain Pathol."},{"key":"59085_CR95","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/jnc.15694","volume":"163","author":"W Michno","year":"2022","unstructured":"Michno, W. et al. Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer\u2019s dementias. J. Neurochem 163, 233\u2013246 (2022).","journal-title":"J. Neurochem"},{"key":"59085_CR96","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2990.2008.00935.x","volume":"34","author":"T Lashley","year":"2008","unstructured":"Lashley, T. et al. Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease. Neuropathol. Appl Neurobiol. 34, 492\u2013505 (2008).","journal-title":"Neuropathol. Appl Neurobiol."},{"key":"59085_CR97","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1021\/bi015685+","volume":"41","author":"W Kalback","year":"2002","unstructured":"Kalback, W. et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer\u2019s disease senile plaques. Biochemistry 41, 922\u2013928 (2002).","journal-title":"Biochemistry"},{"key":"59085_CR98","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","volume":"60","author":"CM Clark","year":"2003","unstructured":"Clark, C. M. et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 60, 1696\u20131702 (2003).","journal-title":"Arch. Neurol."},{"key":"59085_CR99","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41582-019-0222-0","volume":"15","author":"RW Paterson","year":"2019","unstructured":"Paterson, R. W. et al. SILK studies \u2014 capturing the turnover of proteins linked to neurodegenerative diseases. Nat. Rev. Neurol. 15, 419\u2013427 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"59085_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine, T. J. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta neuropathologica 123, 1\u201311 (2012).","journal-title":"Acta neuropathologica"},{"key":"59085_CR101","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791\u20131800 (2002).","journal-title":"Neurology"},{"key":"59085_CR102","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.1039\/c1ob05637a","volume":"9","author":"T Klingstedt","year":"2011","unstructured":"Klingstedt, T. et al. Synthesis of a library of oligothiophenes and their utilization as fluorescent ligands for spectral assignment of protein aggregates. Org. Biomol. Chem. 9, 8356\u20138370 (2011).","journal-title":"Org. Biomol. Chem."},{"key":"59085_CR103","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.15487","volume":"159","author":"E Gkanatsiou","year":"2021","unstructured":"Gkanatsiou, E. et al. Amyloid pathology and synaptic loss in pathological aging. J. Neurochem. 159, 258\u2013272 (2021).","journal-title":"J. Neurochem."},{"key":"59085_CR104","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee, J. et al. Reference measurement procedure for CSF amyloid beta (A\u03b2)(1-42) and the CSF A\u03b2(1-42) \/A\u03b2(1\u221240) ratio - a cross-validation study against amyloid PET. J. Neurochem 139, 651\u2013658 (2016).","journal-title":"J. Neurochem"},{"key":"59085_CR105","doi-asserted-by":"publisher","first-page":"W388","DOI":"10.1093\/nar\/gkab382","volume":"49","author":"Z Pang","year":"2021","unstructured":"Pang, Z. et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 49, W388\u2013w396 (2021).","journal-title":"Nucleic Acids Res."},{"key":"59085_CR106","unstructured":"Szadziewska, A. <https:\/\/BioRender.com\/q15x632> (2025)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59085-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59085-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59085-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T18:02:35Z","timestamp":1745517755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59085-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59085"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59085-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"8 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3889"}}